Clinical Trials
21
Active:9
Completed:12
Trial Phases
3 Phases
Phase 1:14
Phase 2:2
Phase 3:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (20 trials with phase data)• Click on a phase to view related trials
Phase 1
14 (70.0%)Phase 3
4 (20.0%)Phase 2
2 (10.0%)Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)
Phase 3
Completed
- Conditions
- Bacterial Vaginosis
- Interventions
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2019-07-22
- Lead Sponsor
- Starpharma Pty Ltd
- Target Recruit Count
- 586
- Registration Number
- NCT02237950
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Montgomery Women's Health Associates, Montgomery, Alabama, United States
🇺🇸Lynn Institute of the Ozarks, Little Rock, Arkansas, United States
Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)
Phase 3
Completed
- Conditions
- Bacterial Vaginosis
- Interventions
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Starpharma Pty Ltd
- Target Recruit Count
- 637
- Registration Number
- NCT02236156
- Locations
- 🇺🇸
Precision Trials, LLC, Phoenix, Arizona, United States
🇺🇸Medical Center for Clinical Research, San Diego, California, United States
🇺🇸Southern Clinical Research Associates, Metairie, Louisiana, United States
A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis
Phase 3
Completed
- Conditions
- Bacterial Vaginosis
- Interventions
- Drug: PlaceboDrug: 1% SPL7013 Gel
- First Posted Date
- 2012-04-16
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Starpharma Pty Ltd
- Target Recruit Count
- 251
- Registration Number
- NCT01577537
A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis
Phase 3
Completed
- Conditions
- Bacterial Vaginosis
- Interventions
- Drug: PlaceboDrug: 1% SPL7013 Gel
- First Posted Date
- 2012-04-13
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Starpharma Pty Ltd
- Target Recruit Count
- 250
- Registration Number
- NCT01577238
Dose-ranging Study of SPL7013 Gel for the Prevention of Bacterial Vaginosis (BV)
Phase 2
Completed
- Conditions
- Recurrent Bacterial Vaginosis (BV)
- Interventions
- Drug: 1% SPL7013 GelDrug: 3% SPL7013 GelDrug: placebo gel
- First Posted Date
- 2011-09-21
- Last Posted Date
- 2013-11-20
- Lead Sponsor
- Starpharma Pty Ltd
- Target Recruit Count
- 205
- Registration Number
- NCT01437722
- Prev
- 1
- 2
- Next
News
No news found